Serotonin Syndrome

Serotonin syndrome — more precisely called serotonin toxicity, since it is a dose-related toxic effect that occurs on a continuous spectrum rather than as a fixed set of signs — is a potentially life-threatening, drug-induced condition caused by excess serotonergic activity at central and peripheral 5-HT receptors, most importantly the 5-HT2A receptor.^[1] It presents as a triad of neuromuscular abnormalities, autonomic instability, and altered mental status, and it is one of the most common preventable adverse drug interactions a pharmacist is positioned to catch before it happens, not just recognize afterward. Most cases result from combining 2 or more serotonergic drugs that raise serotonin by different mechanisms — most dangerously a monoamine oxidase inhibitor (MAOI) together with any other serotonergic agent — rather than from a single drug at a normal dose. Symptoms typically begin within 24 hours, often within 6 hours, of starting or increasing the dose of a serotonergic drug, or of adding a second one.^[2][3]

• Combining 2 or more serotonergic drugs that raise serotonin by different mechanisms — the most common cause, and the single most preventable one through careful interaction screening.^[2]
• An MAOI combined with any other serotonergic drug — the highest-risk combination; life-threatening cases occur disproportionately with irreversible MAOIs or multidrug combinations rather than with a single serotonergic drug used alone.^[1]
• Overdose or supratherapeutic dosing of a single serotonergic agent.
• A recent dose increase, or the recent addition of a new serotonergic prescription, OTC product, or herbal supplement — most cases begin within 24 hours of this kind of change.
• Multiple prescribers (for example, a family physician, a psychiatrist, and a pain specialist) independently adding serotonergic drugs without a shared, reconciled medication list.
• Undisclosed use of OTC dextromethorphan-containing cough/cold products, St. John's Wort, or illicit stimulants (amphetamines, MDMA) — ask about these specifically, since patients rarely volunteer them as "medications."
• Drug-interaction-driven accumulation: an SSRI inhibiting the CYP2D6 or CYP3A4 metabolism of a serotonergic substrate such as tramadol, dextromethorphan, or methadone, raising its effective serotonergic activity even without any dose change.^[1]
• End-stage renal disease with reduced drug clearance, particularly in a patient on an SSRI who is also receiving hemodialysis.^[1]

History

Serotonin toxicity is a clinical diagnosis — no laboratory test confirms it, and serum serotonin concentration does not correlate with severity and should not be ordered.^[1] Take a complete medication history including prescription drugs, OTC products (especially dextromethorphan-containing cough/cold preparations), herbal and dietary supplements (especially St. John's Wort), and any illicit drug use, along with the exact timing of any recent dose increase or newly added serotonergic drug.^[2]

Nonspecific laboratory findings

Leukocytosis, low serum bicarbonate, and elevated creatinine and transaminases can occur but are nonspecific and are not required for diagnosis.^[1]

Severity spectrum

Complications of severe, untreated toxicity include seizures, rhabdomyolysis, myoglobinuria, metabolic acidosis, renal failure, respiratory failure, disseminated intravascular coagulation, coma, and death.^[1]

Differentiating from neuroleptic malignant syndrome and other mimics

Also consider antidepressant discontinuation syndrome (begins days after stopping or tapering a drug, not after starting or increasing one, and is usually self-limited within about a week), sympathomimetic intoxication, and CNS infection.^[2]

• Identify and discontinue every serotonergic agent contributing to the presentation, including OTC and herbal products.
• Prevent and treat life-threatening hyperthermia and autonomic instability before they progress to organ dysfunction.
• Control agitation and neuromuscular hyperactivity to prevent complications such as rhabdomyolysis and respiratory failure.
• Support vital organ function in severe cases requiring ICU-level care.
• Resolve symptoms — most mild-to-moderate cases resolve within 24 hours of stopping the causative drug(s) and starting supportive care.^[1]
• Prevent recurrence through a documented medication reconciliation and patient education before any serotonergic therapy is restarted or changed.

• Discontinue all serotonergic agents immediately — prescription, OTC, and herbal/illicit.
• Provide supportive care: IV fluids, continuous cardiac monitoring, and supplemental oxygen to keep saturation above 93%.^[1]
• Actively cool the patient for hyperthermia using external measures (cooling blankets, ice packs, evaporative cooling). Antipyretics such as acetaminophen or NSAIDs do not work — the fever is caused by excess muscle activity, not a change in the hypothalamic temperature set point.^[1]
• Use chemical sedation rather than physical restraint for an agitated patient — physical restraint against ongoing muscle contraction can worsen lactic acidosis and hyperthermia.^[1]
• Once resolved, educate the patient and any caregivers on the early symptoms of serotonin toxicity and on telling every future prescriber and pharmacy about the reaction.

Perioperative and procedural patients: methylene blue, used for vasoplegic shock and as a surgical or diagnostic dye, is a potent MAO-A inhibitor. Screen for it in any patient on an SSRI or SNRI before a planned procedure — this is an easy interaction to miss because methylene blue isn't filed mentally as a "psychiatric" drug.^[1]

Renal impairment / hemodialysis: patients with end-stage renal disease on an SSRI who are also receiving hemodialysis have been reported to have increased susceptibility to serotonin toxicity, likely related to reduced clearance — apply extra vigilance with medication reconciliation in this group.^[1]

Older adults: often on multiple serotonergic drugs at once — an antidepressant plus tramadol for pain plus a dextromethorphan-containing cough product, for example — and more vulnerable to the autonomic and CNS effects when toxicity does occur. Reconcile the full medication list, including OTC products, at every visit.

Cancer and palliative care: a patient may simultaneously be on an antidepressant, a serotonergic opioid (tramadol, fentanyl, methadone), and a 5-HT3 antagonist antiemetic such as ondansetron. Health Canada requested that a serotonin syndrome warning be added to the Canadian product monographs for ondansetron and related antiemetics after a 2014 safety review, though the strength of the causative evidence for this specific class remains debated — continue to monitor rather than avoiding these agents outright.^[5][2]

Pregnancy and breastfeeding: if serotonin toxicity occurs, treat the pregnant patient with the same supportive-care approach described above, and discuss antidote use and any ongoing psychiatric drug therapy with obstetric and toxicology specialists given the physiologic changes of pregnancy that can affect drug clearance and dosing.

• Continuous vital-sign and cardiac monitoring during acute treatment, with temperature reassessed at least hourly until trending down.
• Serially re-examine for clonus, hyperreflexia, and muscle tone to track response to treatment — improvement in these findings is the best marker of resolution.
• Most mild-to-moderate cases resolve within 24 hours of stopping the causative drug(s) and starting supportive care; expect a longer course with agents that have a long half-life (fluoxetine/norfluoxetine) or with an irreversible MAOI, where symptoms can persist for days.^[1]
• Before restarting or changing any serotonergic therapy, complete a full medication reconciliation, confirm exactly which combination caused the reaction, and document it clearly so every future prescriber and pharmacist can see it.
• Observe the appropriate washout interval for the specific drug combination before resuming or starting a new serotonergic drug (see Drug Tables).
• Educate the patient to recognize early symptoms — agitation, tremor, sweating — and to seek care promptly if they recur.

1. Confirm that every serotonergic agent has actually been stopped — check specifically for an overlooked OTC dextromethorphan-containing product, herbal supplement, or a recently added drug the patient didn't think to mention.
2. If symptoms persist beyond 24 hours despite confirmed discontinuation and adequate supportive care, reconsider the diagnosis — reassess for neuroleptic malignant syndrome, malignant hyperthermia, CNS infection, or another cause of autonomic instability and hyperthermia.
3. If agitation persists despite an adequate benzodiazepine dose, add or escalate cyproheptadine per the dosing ladder in Drug Tables.
4. If temperature rises above 41.1°C or respiratory compromise develops, escalate immediately to ICU-level sedation, paralysis, and intubation — do not wait for pharmacologic antagonism to take effect first.
5. Involve a poison control centre or medical toxicology consultation for an unclear presentation, an unusual causative combination, or a course that does not follow the expected pattern.

• Treating serotonin syndrome as an exotic, rare diagnosis rather than a common, largely preventable drug interaction that pharmacists are specifically positioned to catch during interaction screening.
• Skipping OTC, herbal, and illicit drug use during medication reconciliation — dextromethorphan-containing cough/cold products and St. John's Wort are easy to miss because patients don't think of them as "medications."
• Missing linezolid or methylene blue as MAOIs because they're filed mentally as an antibiotic and a surgical dye rather than as psychiatric drugs — screen every prescription against the full medication profile regardless of its therapeutic category.
• Assuming a triptan prescribed alongside an SSRI/SNRI automatically means serotonin toxicity is imminent — the FDA/Health Canada warning on this specific combination rests on weaker evidence than the classic MAOI-based combinations, since triptans act at a different receptor subtype than the one implicated in toxicity; counsel appropriately without necessarily withholding a clinically useful drug.^[2]
• Using antipyretics for the hyperthermia — they don't work, because the mechanism is muscle hyperactivity, not a hypothalamic set-point shift.
• Using succinylcholine for paralysis in a severe case — risk of hyperkalemia and worsening rhabdomyolysis; use a non-depolarizing agent instead.
• Giving bromocriptine or dantrolene by extrapolating from neuroleptic malignant syndrome or malignant hyperthermia management — neither is proven effective here, and bromocriptine can make serotonin toxicity worse.
• Restarting or switching a serotonergic drug, or starting an MAOI, without observing the correct washout interval — the single most dangerous, and most preventable, error in this entire chapter.
• Using physical restraint to manage agitation instead of chemical sedation — it worsens muscle activity, lactic acidosis, and hyperthermia.

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Culprit Drug Classes and High-Risk Combinations

MAOI and Serotonergic-Drug Washout Intervals

These are minimum intervals — do not co-prescribe or dispense across them without prescriber confirmation that the interval has genuinely been observed.

Antidote and Supportive Pharmacotherapy

Evidence note: Drug inventory, mechanisms, washout intervals, and antidote dosing reflect the Hunter Serotonin Toxicity Criteria literature and current Canadian and international toxicology reviews.^{[3][4][1][2][5]}